The therapeutic effect of GLP-1 agonists on non-diabetic patients with NAFLD/NASH is currently studied in clinical trials (www.clinicaltrials.gov) [37]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.